Day: June 17, 2021

Company announcement 5/2021 Announcement of financial calendar for Green Hydrogen Systems Kolding, Denmark, 17 June 2021 – With reference to company announcement no. 1/2021 dated 7 June 2021 as published by Green Hydrogen Systems A/S in connection with the initial public offering (the “Offering”) and admission to trading and official listing of Green Hydrogen Systems’ shares on Nasdaq Copenhagen A/S, Green Hydrogen Systems hereby publishes its financial calendar for 2021: Interim report for the period ending 30 June 2021                            18 August 2021 Trading statement for the period ending 30 September 2021                2 November 2021 For more info please contact: Investors: Jens Holm Binger, Head of IR, +45 6065 6525, jhb@greenhydrogen.dk Media: Aleksandra Lozinska, Head of Marketing and Media Relations, +45 4414...

Lundin Energy AB (the “Company”) is pleased to announce that it has priced its senior notes offering (the “Offering”) of USD 1 billion aggregate principal amount of 2.0 percent senior notes, due 2026 (the “2026 Notes”) at a price equal to 99.827 percent of the aggregate principal amount thereof and USD 1 billion aggregate principal amount of 3.1 percent senior notes, due 2031 at a price equal to 99.81 percent of the aggregate principal amount thereof, (the 2031 Notes and together with the 2026 Notes, the “Notes”). Interest will be payable semi-annually. The Offering is expected to close on or about 23 June 2021, subject to customary conditions precedent for similar transactions. The Company intends to use the gross proceeds of the Offering to repay certain amounts outstanding under its corporate credit facility term loans, as well as to...

NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United Kingdom COVID Therapeutics Advisory Panel (UK-CTAP) to support further clinical development of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as an innovative ‘Take Home’ approach for treatment of non-hospitalized patients with COVID-19. This is in response to a call from the UK government for proposals to study therapies that can be delivered at home and avoid hospitalization of patients. Nasal administration of Foralumab is a highly innovative approach to treat patients with autoimmune diseases where the immune system may...

Company announcement 3/2021 Green Hydrogen Systems announces the result of its Initial Public Offering NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017 and nothing herein shall be construed as an offering of securities. No one should purchase or subscribe for any securities in Green Hydrogen Systems A/S (“Green Hydrogen Systems” or the “Company”) except on the basis of information in the prospectus (the “Prospectus”) published by the Company in connection with the offering and potential admission of the Company’s...

GEORGE TOWN, Grand Cayman, June 16, 2021 (GLOBE NEWSWIRE) — StoneCo Ltd. (Nasdaq: STNE) (“Stone”), a leading provider of financial technology solutions that empower merchants to conduct commerce seamlessly across multiple channels, today announces that CADE, the Brazilian antitrust authority, unanimously approved, on this date, the business combination between STNE Participações S.A. (“STNE”), a controlled company of Stone that holds the software investments business of the Stone group in Brazil and Linx S.A. (B3: LINX3; NYSE: LINX) (“Linx”), a leading provider of retail management software in Brazil (“Transaction”), with no restrictions. Stone believes that the business combination with Linx represents a significant value creation opportunity for all stakeholders, including clients, shareholders and employees and will help accelerate...

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the pricing of its initial public offering of 25,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Lyell. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Lyell, are expected to be approximately $425 million. Lyell’s common stock is expected to begin trading on the Nasdaq Global Select Market on June 17, 2021 under the ticker symbol “LYEL.” The offering is expected to close on June 21, 2021, subject to the satisfaction of customary...

NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) — Mountain Crest Acquisition Corp. III (the “Company”) (NASDAQ: MCAEU), a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, today announced that holders of the Company’s units may elect to separately trade the common stock and rights included in its units commencing on or about June 17, 2021. The common stock and rights will trade on the NASDAQ Capital Market (“NASDAQ”) under the symbols MCAE and MCAER, respectively. Units not separated will continue to trade on NASDAQ under the symbol MCAEU. After separation, the common stock and rights may be recombined to create units.  About Mountain Crest Acquisition Corp. III Mountain Crest...